As with many cancers, survival rates for esophageal squamous cell carcinoma (ESCC) are poor when the disease is diagnosed at a later stage whitout any symptoms. Exosomes are 40-150nm small vesicles in blood and other body fluids and have been described as promoters of tumor progression. Although the secretory mechanisms of tumour-associated exosomes are still unclear, the use of circulating exosomes as potential non-invasive biomarkers might become promising. The object of this stduy was to determine whether the circulating exosomes can serve as biomarkers in ESCC.
Serum samples were obtained from 100 patients with ESCC and 100 healthy volunteers. Exosomes were extracted by Total Exosome Isolation Reagent, and purified to selectively capture tumor-asscociated epithelial cell adhesion molecule (EpCAM) positive exosomes by magnetic-bead technique. ELISA was performed to measure the expression of CD9 protein. Cell invasion was measured using transwell chamber. Expression levels were compared by using the Mann-Whitney U test, Friedman or Wilcoxon test., Receiver-operating characteristics (ROC) curve was established to evaluate the diagnostic value of exosome for the differentiation between ESCC patients and controls. Univariate analysis of OS and DFS was performedas outlined by Kaplan-Meier test.
Expression levels of exosomal CD9 were significantly higher in ESCC patients than in healthy individuals (p
Serum exosomal CD9 might represent potential diagnostic and pronostic biomarkers in ESCC in the future.
Clinical trial identification
Legal entity responsible for the study
Zhejiang Cancer Hospital
All authors have declared no conflicts of interest.